[go: up one dir, main page]

ATE350032T1 - Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen - Google Patents

Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Info

Publication number
ATE350032T1
ATE350032T1 AT99932296T AT99932296T ATE350032T1 AT E350032 T1 ATE350032 T1 AT E350032T1 AT 99932296 T AT99932296 T AT 99932296T AT 99932296 T AT99932296 T AT 99932296T AT E350032 T1 ATE350032 T1 AT E350032T1
Authority
AT
Austria
Prior art keywords
inhibitors
pain
protein kinase
epsilone
epsilon
Prior art date
Application number
AT99932296T
Other languages
English (en)
Inventor
Robert O Messing
Jon D Levine
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE350032T1 publication Critical patent/ATE350032T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99932296T 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen ATE350032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9175598P 1998-07-06 1998-07-06
US10376398P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
ATE350032T1 true ATE350032T1 (de) 2007-01-15

Family

ID=26784298

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932296T ATE350032T1 (de) 1998-07-06 1999-07-06 Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen

Country Status (10)

Country Link
EP (1) EP1093379B1 (de)
JP (1) JP2002519391A (de)
AT (1) ATE350032T1 (de)
AU (1) AU764760B2 (de)
CA (1) CA2336709A1 (de)
DE (1) DE69934689T2 (de)
ES (1) ES2283120T3 (de)
IL (1) IL140716A0 (de)
NZ (1) NZ508767A (de)
WO (1) WO2000001415A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335220B2 (en) 2004-11-05 2008-02-26 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
AU2003234185C1 (en) 2002-04-22 2009-11-19 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
JP4675109B2 (ja) * 2003-05-16 2011-04-20 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 離脱症状における使用のためのプロテインキナーゼcペプチド
CA2539132A1 (en) 2003-09-16 2005-03-24 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
CA2603868A1 (en) * 2005-04-02 2006-10-12 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin Assays for determining compounds which modulate tram phosphorylation
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
EP2177510A1 (de) 2008-10-17 2010-04-21 Universität des Saarlandes Allosterische Proteinkinasemodulatoren
JP2010090176A (ja) * 2010-01-26 2010-04-22 Board Of Trustees Of The Leland Stanford Junior Univ 離脱症状における使用のためのプロテインキナーゼcペプチド
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
JP6243850B2 (ja) * 2012-11-26 2017-12-06 学校法人近畿大学 抗がん剤による末梢神経障害の予防、治療、または軽減剤
EP3180003B1 (de) 2014-07-01 2022-01-12 The Regents of the University of California Pkc-epsilon-inhibitoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.

Also Published As

Publication number Publication date
WO2000001415A3 (en) 2000-04-13
CA2336709A1 (en) 2000-01-13
DE69934689D1 (de) 2007-02-15
AU4863199A (en) 2000-01-24
AU764760B2 (en) 2003-08-28
DE69934689T2 (de) 2007-10-25
JP2002519391A (ja) 2002-07-02
EP1093379B1 (de) 2007-01-03
WO2000001415A2 (en) 2000-01-13
NZ508767A (en) 2003-12-19
IL140716A0 (en) 2002-02-10
ES2283120T3 (es) 2007-10-16
EP1093379A2 (de) 2001-04-25

Similar Documents

Publication Publication Date Title
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MX9803563A (es) Preparacion terapeutica para la administracion transdermica de principios activos.
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
AU4923093A (en) Inhibitors of metazoan parasite proteases
BRPI0411364A (pt) compostos tendo atividade inibidora de fosfatidilinositol 3-cinase e métodos de uso dos mesmos
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
DK0876158T3 (da) Ny medicinsk anvendelse af en ACE-inhibitor til behandling af mavesurhedssymptomer
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
AU5434899A (en) Cancer treatment

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties